Alvotech (ALVO)
NASDAQ: ALVOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALVO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.47B
- Forward P/E
- 19.46
- EPS (TTM)
- -$0.82
- Dividend yield
- None
- 52-week range
- 2.94 – 6.53
- Day range
- 4.09 – 4.29
- Volume / Avg
- 826.57K / 1.13M
- Beta
- —
- Shares outstanding
- 356.82M
52-week range
ALVO stock today
Shares of Alvotech (ALVO) finished lower on Nov 20 at $4.12, a drop of 3.96% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, ALVO sits in the middle of its 52-week range of $2.94 to $6.53: 36.9% below the high, set on Oct 5, 2026 and 40.1% above the low. ALVO is down 19.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 19.8%.
Alvotech has posted a net loss over the last twelve months (EPS of -$0.82), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alvotech
Company profileAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Ms. Lisa Graver
- Headquarters
- Luxembourg
- Employees
- 1,279
- Website
- alvotech.com
Financial highlights
Full financialsIn fiscal 2025, Alvotech generated $586.3 million in revenue, up 19.7% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $27.9 million, for a net margin of 4.8% versus a median of -276.0% in the prior 5 years. Gross margin was 59.8% (down from 62.2%) and operating margin 13.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $586.32M | $489.68M | $91.43M | $83.03M | $36.77M |
| Growth | +19.74% | +435.56% | +10.12% | +125.79% | -44.80% |
| Net income | $27.92M | $-231.86M | $-551.73M | $-513.58M | $-101.50M |
| EPS (diluted) | $0.10 | $-0.87 | $-2.43 | $-2.60 | $-0.92 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$7.50+82.04%
- Strong buy 2
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.02 vs $-0.01
- Surprise
- -100.00%
ALVO news
All ALVO news- Amneal's Xolair Biosimilar Adcomfo Gets EU Marketing Authorization For Allergic ConditionsNasdaqALVO, AMRX, NVS, UHAL.B
- Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA as it expects Q4 to be “the strongest” in company historySeeking Alpha
- Alvotech falls on Q3 resultsSeeking Alpha
- Alvotech (ALVO) Q3 2026 Earnings Call TranscriptNasdaq
- Alvotech reports Q3 resultsSeeking Alpha
- Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateGlobeNewswire
- Alvotech birtir árshlutauppgjör fyrstu níu mánaða ársins 2026GlobeNewswire
- Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateGlobeNewswire
Alvotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs ALVO |
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs ALVO |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs ALVO |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs ALVO |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs ALVO |
| NVAXNovavax Inc. | 7.47 | -3.24% | $1.23B | vs ALVO |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs ALVO |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs ALVO |
Indexes, lists and sector
Alvotech stock FAQ
What is Alvotech's stock price today?
ALVO last traded at $4.12 as of Nov 20, 4:00 PM EST, down 3.96% on the day. Prices are delayed at least 15 minutes.
Who is Alvotech's CEO?
Ms. Lisa Graver is the chief executive officer of Alvotech, which has about 1,279 employees.
What is the ALVO 52-week high?
The 52-week high for ALVO is $6.53 and the 52-week low is $2.94. The stock is currently 36.9% below its high.